<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389220</url>
  </required_header>
  <id_info>
    <org_study_id>05EU01</org_study_id>
    <nct_id>NCT00389220</nct_id>
  </id_info>
  <brief_title>Limus Eluted From A Durable Versus ERodable Stent Coating</brief_title>
  <acronym>LEADERS</acronym>
  <official_title>A Randomized Comparison of a Biolimus-Eluting Stent With a Sirolimus-Eluting Stent for Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the BioMatrix Flex (Biolimus A9-Eluting) stent system
      with the Cypher SELECT (Sirolimus-Eluting) stent system in a non-inferiority trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the safety and efficacy of the BioMatrix Flex (Biolimus A9-Eluting) stent system with
      the Cypher SELECT (Sirolimus-Eluting) stent system in a prospective, multi-center,
      randomized, controlled, non-inferiority trial in patients undergoing percutaneous coronary
      intervention in routine clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>9 month</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>30 days</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>30 days</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment binary restenosis rate as assessed by QCA.</measure>
    <time_frame>9 month</time_frame>
    <description>In-stent and in-segment binary restenosis rate as assessed by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment minimal luminal diameter (MLD) as assessed by QCA.</measure>
    <time_frame>9 month</time_frame>
    <description>In-stent and in-segment minimal luminal diameter (MLD) as assessed by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment percent diameter stenosis (%DS).</measure>
    <time_frame>9 month</time_frame>
    <description>In-segment percent diameter stenosis (%DS) as assessed by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment late luminal loss</measure>
    <time_frame>9 month</time_frame>
    <description>In-stent and in-segment late luminal loss as assessed by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success, lesion success and procedural success.</measure>
    <time_frame>at implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>6 month</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>2 years</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>6 month</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>9 month</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>2 year</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>3 year</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>4 year</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>5 year</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>3 year</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>4 year</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) in the overall population according to the ARC definitions.</measure>
    <time_frame>5 year</time_frame>
    <description>Major adverse cardiac events (MACE) in the overall population defined as composite of cardiac death,myocardial infarction (Q-wave and Non-Q wave)justified target vessel revascularization and Justified and non-justified target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>6 month</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>9 month</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>1 year</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>2 years</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>3 years</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>4 years</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All deaths</measure>
    <time_frame>5 years</time_frame>
    <description>All deaths (cardiac and non-cardiac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 month</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>9 month</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>3 years</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>4 years</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>5 years</time_frame>
    <description>Myocardial infarction (Q-wave and NQWMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>6 month</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>9 month</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>1 year</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>2 years</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>3 years</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>4 years</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical stent thrombosis.</measure>
    <time_frame>5 years</time_frame>
    <description>Angiographic and clinical stent thrombosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1707</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>BioMatrix Flex stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher Select stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary stent placement with Sirolimus coated stent with durable polymer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary stent placement</intervention_name>
    <description>Coronary stent placement</description>
    <arm_group_label>BioMatrix Flex stent</arm_group_label>
    <arm_group_label>Cypher Select stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years;

          -  Symptomatic coronary artery disease including patients with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation myocardial
             infarction and ST-elevation myocardial infarction;

          -  Presence of one or more coronary artery stenoses &gt;50% in a native coronary artery or a
             saphenous bypass graft from 2.25 to 3.5 mm in diameter that can be covered with one or
             multiple stents;

          -  No limitation on the number of treated lesions, and vessels, and lesion length

        Exclusion Criteria:

          -  Pregnancy;

          -  Known intolerance to aspirin, clopidogrel, heparin, stainless steel, Sirolimus,
             Biolimus or contrast material;

          -  Inability to provide informed consent;

          -  Currently participating in another trial before reaching first endpoint;

          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained
             throughout the perisurgical period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Windecker, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universitätsklinik, Swiss Cardiovacular Center Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis, Cardiologisch Centrum, Moorselbaan 164</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L'Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques Cartier, Service de Coronarographie, 6, Avenue du Noyer Lambert</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig, Innere Medizin/Kardiologie, Struimpellstrasse 39</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munchen, Medizinische Klinik Kardiologie, Ziemssenstrasse 1</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen der Stad München, Abteilung für Kardiologie und Pnemlogie, Englschalkstrasse 77</name>
      <address>
        <city>Munich</city>
        <zip>D-8000</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rotterdam Erasmus, Thoraxcentrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland Sp. z o.o.</name>
      <address>
        <city>Dąbrowa Górnicza</city>
        <zip>43100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik, Swiss Cardiovacular Center Bern, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich, Director of Invasive Cardiology, Rämistrasse 100</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital, Sydney Street</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Spain</country>
  </removed_countries>
  <results_reference>
    <citation>Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008 Sep 27;372(9644):1163-73. doi: 10.1016/S0140-6736(08)61244-1. Epub 2008 Aug 31.</citation>
    <PMID>18765162</PMID>
  </results_reference>
  <results_reference>
    <citation>Garg S, Sarno G, Serruys PW, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P, Windecker S. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention. 2010 Jun;6(2):233-9. doi: 10.4244/.</citation>
    <PMID>20562074</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarno G, Garg S, Onuma Y, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, van Geuns RJ, Eerdmans P, Garcia-Garcia HM, van Es GA, Goedhart D, de Vries T, Jüni P, Meier B, Windecker S, Serruys P. The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). Am J Cardiol. 2010 Feb 15;105(4):475-9. doi: 10.1016/j.amjcard.2009.09.055. Epub 2010 Jan 5.</citation>
    <PMID>20152241</PMID>
  </results_reference>
  <results_reference>
    <citation>Wykrzykowska JJ, Serruys PW, Onuma Y, de Vries T, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, Wijns W, Morice MC, di Mario C, van Geuns RJ, Juni P, Windecker S. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. JACC Cardiovasc Interv. 2009 Sep;2(9):861-70. doi: 10.1016/j.jcin.2009.05.024.</citation>
    <PMID>19778775</PMID>
  </results_reference>
  <results_reference>
    <citation>Wykrzykowska JJ, Räber L, de Vries T, Bressers M, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Regar E, Jüni P, Windecker S, Serruys PW. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. EuroIntervention. 2009 Aug;5(3):310-7.</citation>
    <PMID>19736154</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2006</study_first_submitted>
  <study_first_submitted_qc>October 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Disease</keyword>
  <keyword>Coronary Stenosis</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary Restenosis</keyword>
  <keyword>Drug Eluting Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

